Randomized Trials of Prostate Cancer Screening

[摘要] Since the introduction of widespread prostate-specific antigen (PSA)-based prostate cancer screening, there has been a considerable stage migration.1 Prior studies have shown that PSA screening reduces the risk of advanced disease compared with no screening,2,3 but there were insufficient data to prove that screening saves lives. Until recently, randomized trials demonstrating Level I evidence have not been available to determine whether prostate cancer screening leads to a mortality benefit. In March 2009, the European Randomized Study of Screening for Prostate Cancer (ERSPC) and Prostate, Lung, Colorectal, and Ovarian (PLCO) trials reported on mortality results.

[学科分类] 基础医学